Search

Background: Lichenoid drug eruption (LDE) is an uncommon cutaneous adverse drug reaction, where a variety of drugs used in day-to-day clinical practice have been implicated. Objective: To describe the clinico-demographic characteristics of patients with LDE and to identify the most likely drugs involved. Methods: In this prospective, observational study, consecutive patients with LDE presenting to the dermatology department of a tertiary teaching hospital were included. The clinico-demographic profile of patients with LDE and implicated drugs was noted. Treatment of drug reaction along with outcome was also documented. Naranjo adverse drug reaction probability scale was used for causality assessment of the drug reactions. A thorough literature review on LDE was also undertaken due to the paucity of existing literature. Results: A total of 15 patients (11 males and 4 females) with LDE were evaluated. Their age ranged from 37 to 61 years, with a mean of 51.53 ± 7.59 years. Anti-hypertensive medications (40) were the most common culprit agent, followed by antitubercular drugs (33.4), anti-diabetic agents (13.3), and others (13.3). The latent period (time from drug initiation to the appearance of a cutaneous eruption) varied from 15 days to 6 months (mean 2.2 months). Cutaneous involvement was generalized in 73.4 and photo-distributed lesions in 26.6. Drug provocation test was done to identify the culprit drug. According to the Naranjo adverse drug reaction probability scale, one-third of LDEs were 'definite,' whereas two-thirds were designated as 'probable.' Conclusion: LDE is more common in the elderly population. The latent period is comparatively longer in LDE than in other common drug reactions. Prompt recognition and withdrawal of suspected drug are essential to minimize disease morbidity. Keywords: Cutaneous adverse drug reaction, lichenoid drug eruption, Naranjo causality assessment, Author(s): Dibyendu B. Bhanja (corresponding author) [1]; Abheek Sil [2]; Arunasis Maiti [1]; Surajit K. Biswas [3] Introduction Cutaneous adverse drug reactions (CADR) are commonly encountered in day-to-day clinical practice, [...]

Addisonian-like acrofacial hyperpigmentation following long-term hydroxychloroquine therapy in oral lichen planus. Based on distinctive clinical features, temporal association with intake of cyclosporine, and ruling out other obvious causes of hyperpigmentation, a diagnosis of cyclosporine-induced cutaneous hyperpigmentation was established. Dear Editor, Cyclosporine, a calcineurin inhibitor, is being increasingly used as an immunosuppressant for prophylaxis in organ transplantation and various immune regulatory disorders involving dermatological, hematological, renal, gastroenterological, neurological, and musculoskeletal systems.1 Here we describe a rarely documented side effect, cutaneous hyperpigmentation, following treatment with cyclosporine. [Extracted from the article]

Sudden appearance of purpuric lesions around both eyes following severe bouts of vomiting in a pregnant female (hyperemesis gravidarum) without any other apparent cause clinched the diagnosis of post-emesis periorbital purpura. Similar periorbital purpura/ecchymosis imitating "raccoon eyes" appearance in metastatic neuroblastoma is brought about by obstruction of the palpebral vessels by infiltration of tumor cells in and around the orbits. Abrupt onset facial purpuric eruptions following suggestive history of severe vomiting bouts in pregnancy should raise suspicion of post-emesis periorbital purpura. [Extracted from the article]

Competing Interests: There are no conflicts of interest.